$ROIV news
The latest ROIV stock news: headlines, filings, AI summaries and sentiment for $ROIV, updated around the clock.
- Roivant Sciences Reports Q2 2026 Results with LISRAYA Commercial Launch and Positive Clinical Data
- Roivant Sciences Ltd. - 10-Q Filing
- Roivant Sciences Ltd. - 8-K Filing
- Midday Market Update: SpaceX Revenue Surge and Super Micro Guidance Boost Stocks
- Roivant Sciences Shares Rise Following Positive Late-Stage Trial Results for Lisraya
- Roivant Sciences Ltd. - 8-K Filing
- Roivant Shares Drop After Immunovant Trial Fails
- Roivant Sciences Ltd. - 8-K Filing
- Roivant Sciences Reports Positive Phase 2 Results for Mosliciguat in Pulmonary Hypertension
- Roivant Sciences Shares Rise After Positive PH-ILD Trial Results
- Roivant Sciences Shares Rise on Positive Mosliciguat Trial Results
- Roivant Sciences Ltd. - 8-K Filing
- Biggest Stock Movers on Tuesday Include ZIM, NVS and Quantum Computing Stocks
- Premarket Stock Movements: Peloton, Roivant Sciences, Boston Scientific Among Major Movers
- Roivant Sciences Ltd. - 8-K Filing
- Priovant Therapeutics Receives FDA Approval for Brepocitinib to Treat Dermatomyositis
- Arbutus Biopharma and Roivant Sciences Sue Over Patents Related to Pfizer-BioNTech's COVID-19 Vaccine
- Roivant Sciences Reports Profitability, Shares Rise 15%
- Roivant Reports Earnings Beat Despite Revenue Miss
- Roivant Sciences Anticipates $950M Payment from Moderna in July
- Roivant Sciences Reports Q4 2025 Earnings and Key Clinical Updates
- Roivant Sciences Rises on Positive Phase 2 Trial Data from Immunovant's Drug
- Roivant Sciences Ltd. - 10-K Filing
- Roivant Sciences Ltd. - 8-K Filing
- Roivant Sciences Reports Q4 GAAP EPS of $0.28 Beats Estimates but Revenue Misses
- Hedge Fund ADAR1 Capital Management Invests $36 Million in Denali Therapeutics Following FDA Approval